Ann: COVID19 Vaccine Feasibility Assessment, page-376

Hello dear fellow Investors,
I have a feeling that feasibility may have already been completed. Tricky stuff is that Astrazeneca has got a bit of
hype with a rare side effects, so this may need some sorting
out. It’s hard to imagine if IDT were going to be assigned a
different vaccine when CSL is doing AstraZenca.

If there is a possibility of Pfizer, then also Ann could be delayed
to avoid an alteration to the previous approach. Alternatively if Astrazeneca has been discussed, they might be looking at possibility of Pfizer/J& J or other types and this will obviously take time. I have a feeling that market perhaps got a sniff today or possibly second guessing about this and possibly a delayed
announcement ( no idea how long though). However, in any circumstances, IDT is likely to be granted ( rest assured) a significant role in this. Believers in this would still stick with the stock, although a little short term loss but almost certain to have a massive re rate of SP is inevitable. This is logical and not just emotional. Good opportunity at every dip. IMHO, DYOR